» Articles » PMID: 34723229

WHO International Standard for Evaluation of the Antibody Response to COVID-19 Vaccines: Call for Urgent Action by the Scientific Community

Overview
Journal Lancet Microbe
Date 2021 Nov 1
PMID 34723229
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

The first WHO International Standard and International Reference Panel for anti-SARS-CoV-2 immunoglobulin were established by the WHO Expert Committee on Biological Standardization in December, 2020. The WHO International Antibody Standards are intended to serve as global reference reagents, against which national reference preparations or secondary standards can be calibrated. Calibration will facilitate comparison of results of assays (eg, of the neutralising antibody response to candidate COVID-19 vaccines) conducted in different countries. Use of these standards is expected to contribute to better understanding of the immune response, and particularly of the correlates of protection. This Personal View provides some technical details of the WHO Antibody Standards for SARS-CoV-2, focusing specifically on the use of these standards for the evaluation of the immune response to COVID-19 vaccines, rather than other applications (eg, diagnostic or therapeutic). The explanation with regard to why rapid adoption of the standards is crucial is also included, as well as how funders, journals, regulators, and ethics committees could drive adoption in the interest of public health.

Citing Articles

Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens.

Cruz P, Lam J, Abdalla J, Bell S, Bytyci J, Brosh-Nissimov T Vaccines (Basel). 2025; 13(1).

PMID: 39852798 PMC: 11768488. DOI: 10.3390/vaccines13010019.


Challenges and Approaches to Establishing Multi-Pathogen Serosurveillance: Findings from the 2023 Serosurveillance Summit.

Carcelen A, Kong A, Takahashi S, Hegde S, Jaenisch T, Chu M Am J Trop Med Hyg. 2024; 111(5):1145-1152.

PMID: 39226906 PMC: 11542533. DOI: 10.4269/ajtmh.24-0296.


Conference Report: LPMHealthcare Emerging Viruses 2023 (EVOX23): Pandemics-Learning from the Past and Present to Prepare for the Future.

Jenkins F, Mapulanga T, Thapa G, da Costa K, Temperton N Pathogens. 2024; 13(8).

PMID: 39204279 PMC: 11357271. DOI: 10.3390/pathogens13080679.


Surface Plasmon Resonance Immunosensor for Direct Detection of Antibodies against SARS-CoV-2 Nucleocapsid Protein.

Lisyte V, Kausaite-Minkstimiene A, Brasiunas B, Popov A, Ramanaviciene A Int J Mol Sci. 2024; 25(16).

PMID: 39201259 PMC: 11354133. DOI: 10.3390/ijms25168574.


Governing with public engagement: an anticipatory approach to human genome editing.

Barlevy D, Juengst E, Kahn J, Moreno J, Lambert L, Charo A Sci Public Policy. 2024; 51(4):680-691.

PMID: 39035203 PMC: 11258878. DOI: 10.1093/scipol/scae010.